National multicentre registry of the French Association of Urology (AFU) dedicated to kidney cancer.
Over 21,000 patients with detailed clinical, biological and follow-up data.
UroCCR aggregates clinical, therapeutic and follow-up data from over 21,000 kidney cancer patients, prospectively collected across 40+ French oncological urology centres.
Age, sex, performance scores, comorbidities, diagnostic circumstances.
TNM classification, Fuhrman nuclear grade, histological architecture.
Histological subtype (clear cell, papillary, chromophobe), PD-L1, prognostic biomarkers.
Surgery, targeted therapies, immunotherapy, complete regimens with dates.
Presence, location, time to recurrence, re-treatment.
Prospective follow-up, overall survival, recurrence-free survival, death.
UroCCR meets the needs of urological oncologists, researchers and industry partners in renal oncology.
Incidence, prevalence, risk factors, prognostic scores, recurrence-free survival.
Efficacy of targeted therapies and immunotherapies, optimal sequences, regimen comparison.
Treatment toxicities, real-world tolerability profile, safety signals.
UroCCR is authorised by CNIL and managed by the French Association of Urology. Data are collected prospectively with patient consent and in compliance with GDPR.
Contact our team to explore UroCCR data for your study.